As­traZeneca tri­al shows mod­est ben­e­fit in ovar­i­an can­cer, but doc­tors say it's hard to ap­ply find­ings: #AS­CO23

CHICA­GO — Adding As­traZeneca’s Imfinzi and Lyn­parza to the treat­ment reg­i­men for pa­tients with ad­vanced ovar­i­an can­cer and no BR­CA mu­ta­tion ex­tend­ed pro­gres­sion-free sur­vival (PFS) by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.